Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68, 394, 10.3322/caac.21492 Yang, 2020, Precision management of advanced non-small cell lung cancer, Annu. Rev. Med., 71, 117, 10.1146/annurev-med-051718-013524 Molina, 2008, Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship, Mayo Clin. Proc., 83, 584, 10.1016/S0025-6196(11)60735-0 Sun, 2007, Lung cancer in never smokers--a different disease, Nat. Rev. Cancer, 7, 778, 10.1038/nrc2190 Stella, 2012, Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies, Respir. Med., 106, 173, 10.1016/j.rmed.2011.10.015 Lin, 2016, Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs, J. Thorac. Oncol., 11, 556, 10.1016/j.jtho.2015.12.103 Noronha, 2014, The importance of brain metastasis in EGFR mutation positive NSCLC patients, Chemother. Res. Pract., 2014, 856156 de Muga, 2010, Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas, Mod. Pathol., 23, 703, 10.1038/modpathol.2010.45 Mitsudomi, 2013, Surgery for NSCLC in the era of personalized medicine, Nat. Rev. Clin. Oncol., 10, 235, 10.1038/nrclinonc.2013.22 Wheeler, 2010, Understanding resistance to EGFR inhibitors-impact on future treatment strategies, Nat. Rev. Clin. Oncol., 7, 493, 10.1038/nrclinonc.2010.97 Sharma, 2007, Epidermal growth factor receptor mutations in lung cancer, Nat. Rev. Cancer, 7, 169, 10.1038/nrc2088 Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N. Engl. J. Med., 350, 2129, 10.1056/NEJMoa040938 Huang, 2020, Inhibition of alternative cancer cell metabolism of EGFR mutated non-small cell lung cancer serves as a potential therapeutic strategy, Cancers, 12, 181, 10.3390/cancers12010181 Kim, 2018, Enhanced glycolysis supports cell survival in EGFR-mutant lung adenocarcinoma by inhibiting autophagy-mediated EGFR degradation, Cancer Res., 78, 4482, 10.1158/0008-5472.CAN-18-0117 Makinoshima, 2014, Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma, J. Biol. Chem., 289, 20813, 10.1074/jbc.M114.575464 Su, 2006, Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors, Clin. Cancer Res., 12, 5659, 10.1158/1078-0432.CCR-06-0368 Yuan, 2019, The emerging treatment landscape of targeted therapy in non-small-cell lung cancer, Signal Transduct. Target. Ther., 4, 61, 10.1038/s41392-019-0099-9 Papadimitrakopoulou, 2018, LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study, Ann. Oncol., 29, 10.1093/annonc/mdy424.064 Ramalingam, 2018, LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study, Ann. Oncol., 29, 10.1093/annonc/mdy424.063 Yu, 2013, Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers, Clin. Cancer Res., 19, 2240, 10.1158/1078-0432.CCR-12-2246 Godin-Heymann, 2008, The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor, Mol. Cancer Ther., 7, 874, 10.1158/1535-7163.MCT-07-2387 Ohashi, 2012, Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1, Proc. Natl. Acad. Sci. U. S. A., 109, E2127, 10.1073/pnas.1203530109 Yun, 2008, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP, Proc. Natl. Acad. Sci. U. S. A., 105, 2070, 10.1073/pnas.0709662105 Janne, 2015, AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer, N. Engl. J. Med., 372, 1689, 10.1056/NEJMoa1411817 O'Kane, 2018, Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials, Curr. Oncol., 25, S28, 10.3747/co.25.3796 Soria, 2018, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer, N. Engl. J. Med., 378, 113, 10.1056/NEJMoa1713137 Le, 2019, Newer-generation EGFR inhibitors in lung cancer: how are they best used?, Cancers, 11, 366, 10.3390/cancers11030366 Thress, 2015, Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, Nat. Med., 21, 560, 10.1038/nm.3854 Cheng, 2016, Recent progress on third generation covalent EGFR inhibitors, Bioorg. Med. Chem. Lett., 26, 1861, 10.1016/j.bmcl.2016.02.067 Zhou, 2009, Novel mutant-selective EGFR kinase inhibitors against EGFR T790M, Nature, 462, 1070, 10.1038/nature08622 Wang, 2017, Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation EGFR TKIs and shifts allelic configuration at resistance, J. Thorac. Oncol., 12, 1723, 10.1016/j.jtho.2017.06.017 Niederst, 2015, The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies, Clin. Cancer Res., 21, 3924, 10.1158/1078-0432.CCR-15-0560 Mok, 2017, Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer, N. Engl. J. Med., 376, 629, 10.1056/NEJMoa1612674 To, 2019, Single and dual targeting of mutant EGFR with an allosteric inhibitor, Cancer Discov., 9, 926, 10.1158/2159-8290.CD-18-0903 Uchibori, 2017, Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer, Nat. Commun., 8, 14768, 10.1038/ncomms14768 Xu, 2020, Checkpoint inhibitor immunotherapy in kidney cancer, Nat. Rev. Urol., 17, 137, 10.1038/s41585-020-0282-3 Riley, 2019, Delivery technologies for cancer immunotherapy, Nat. Rev. Drug Discov., 18, 175, 10.1038/s41573-018-0006-z Ancevski Hunter, 2018, PD-L1 testing in guiding patient selection for PD-1/PD-L1 inhibitor therapy in lung cancer, Mol. Diagn. Ther., 22, 1, 10.1007/s40291-017-0308-6 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med., 373, 123, 10.1056/NEJMoa1504627 Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7 Rittmeyer, 2017, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, 389, 255, 10.1016/S0140-6736(16)32517-X Reck, 2016, Pembrolizumab versus Chemotherapy for PD-L1-positive non-small-cell lung cancer, N. Engl. J. Med., 375, 1823, 10.1056/NEJMoa1606774 Meyers, 2018, Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer, Curr. Oncol., 25, e324, 10.3747/co.25.3976 Baker, 2016, A critical review of recent developments in radiotherapy for non-small cell lung cancer, Radiat. Oncol., 11, 115, 10.1186/s13014-016-0693-8 Kola, 2004, Can the pharmaceutical industry reduce attrition rates?, Nat. Rev. Drug Discov., 3, 711, 10.1038/nrd1470 Zamboni, 2012, Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance, Clin.Cancer Res., 18, 3229, 10.1158/1078-0432.CCR-11-2938 Steffensen, 2013, Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study, Int. J. Gynecol. Cancer, 23, 73, 10.1097/IGC.0b013e3182775fae Levine, 2013, Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS malignancy consortium study 047, J. Clin. Oncol., 31, 58, 10.1200/JCO.2012.42.4648 McBride, 2001, Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma, Leuk. Lymphoma, 42, 89, 10.3109/10428190109097680 Arrieta, 2012, First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial, Br. J. Cancer, 106, 1027, 10.1038/bjc.2012.44 Socinski, 2012, Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non–small-cell lung cancer: final results of a phase III trial, J. Clin. Oncol., 30, 2055, 10.1200/JCO.2011.39.5848 Socinski, 2013, Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer, Ann. Oncol., 24, 2390, 10.1093/annonc/mdt235 Von Hoff, 2013, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N. Engl. J. Med., 369, 1691, 10.1056/NEJMoa1304369 Walther, 2000, Viral vectors for gene transfer, Drugs, 60, 249, 10.2165/00003495-200060020-00002 Ledford, 2015, Cancer-fighting viruses win approval, Nature, 526, 622, 10.1038/526622a Miest, 2014, New viruses for cancer therapy: meeting clinical needs, Nat. Rev. Microbiol., 12, 23, 10.1038/nrmicro3140 Colombo, 2012, Biological applications of magnetic nanoparticles, Chem. Soc. Rev., 41, 4306, 10.1039/c2cs15337h Tseng, 2016, Remote control of light-triggered virotherapy, ACS Nano, 10, 10339, 10.1021/acsnano.6b06051 Zincarelli, 2008, Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection, Mol. Ther., 16, 1073, 10.1038/mt.2008.76 Liao, 2018, Micro-scale RNA interference using iron oxide nanoparticle-modified lentivirus, ChemNanoMat, 4, 98, 10.1002/cnma.201700251 Mura, 2013, Stimuli-responsive nanocarriers for drug delivery, Nat. Mater., 12, 991, 10.1038/nmat3776 Corbet, 2017, Tumour acidosis: from the passenger to the driver's seat, Nat. Rev. Cancer, 17, 577, 10.1038/nrc.2017.77 Tseng, 2018, Targeting tumor microenvironment by bioreduction-activated nanoparticles for light-triggered virotherapy, ACS Nano, 12, 9894, 10.1021/acsnano.8b02813 Muthana, 2015, Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting, Nat. Commun., 6, 8009, 10.1038/ncomms9009 Bishop, 2015, Exploring the role of polymer structure on intracellular nucleic acid delivery via polymeric nanoparticles, J. Control. Release, 219, 488, 10.1016/j.jconrel.2015.09.046 Colombani, 2017, Self-assembling complexes between binary mixtures of lipids with different linkers and nucleic acids promote universal mRNA, DNA and siRNA delivery, J. Control. Release, 249, 131, 10.1016/j.jconrel.2017.01.041 Tseng, 2007, Development of poly(amino ester glycol urethane)/siRNA polyplexes for gene silencing, Bioconjug. Chem., 18, 1383, 10.1021/bc060382j Bykov, 2018, Targeting mutant p53 for efficient cancer therapy, Nat. Rev. Cancer, 18, 89, 10.1038/nrc.2017.109 Blandino, 2018, New therapeutic strategies to treat human cancers expressing mutant p53 proteins, J. Exp. Clin. Cancer Res., 37, 30, 10.1186/s13046-018-0705-7 Wang, 2009, p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of slug, Nat. Cell Biol., 11, 694, 10.1038/ncb1875 Liu, 2008, ROS and p53: a versatile partnership, Free Radic. Biol. Med., 44, 1529, 10.1016/j.freeradbiomed.2008.01.011 Tseng, 2015, Highly specific in vivo gene delivery for p53-mediated apoptosis and genetic photodynamic therapies of tumour, Nat. Commun., 6, 6456, 10.1038/ncomms7456 Li, 2017, Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment, Biomater. Sci., 5, 77, 10.1039/C6BM00449K Chen, 2012, Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab, BMC Med., 10, 28, 10.1186/1741-7015-10-28 Stahlhut, 2015, Combinatorial action of MicroRNAs let-7 and miR-34 effectively synergizes with Erlotinib to suppress non-small cell lung cancer cell proliferation, Cell Cycle, 14, 2171, 10.1080/15384101.2014.1003008 Shah, 2016, microRNA therapeutics in cancer - an emerging concept, EBioMedicine, 12, 34, 10.1016/j.ebiom.2016.09.017 Lennox, 2011, Chemical modification and design of anti-miRNA oligonucleotides, Gene Ther., 18, 1111, 10.1038/gt.2011.100 Lin, 2013, Extracellular delivery of modified oligonucleotide and superparamagnetic iron oxide nanoparticles from a degradable hydrogel triggered by tumor acidosis, Biomaterials, 34, 4387, 10.1016/j.biomaterials.2013.02.058 Ifediba, 2012, In vivo imaging of the systemic delivery of small interfering RNA, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 4, 428, 10.1002/wnan.1158 Lu, 2016, siRNA delivered by EGFR-specific scFv sensitizes EGFR-TKI-resistant human lung cancer cells, Biomaterials, 76, 196, 10.1016/j.biomaterials.2015.10.036 Jee, 2014, Alteration of miRNA activity via context-specific modifications of Argonaute proteins, Trends Cell Biol., 24, 546, 10.1016/j.tcb.2014.04.008 Roskoski, 2019, Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers, Pharmacol. Res., 139, 395, 10.1016/j.phrs.2018.11.014 Meanwell, 2011, Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety, Chem. Res. Toxicol., 24, 1420, 10.1021/tx200211v Li, 2017, Aptamer-conjugated chitosan-anchored liposomal complexes for targeted delivery of Erlotinib to EGFR-mutated lung cancer cells, AAPS J., 19, 814, 10.1208/s12248-017-0057-9 Li, 2017, Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer, Biomaterials, 145, 56, 10.1016/j.biomaterials.2017.08.030 Zheng, 2017, mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy, J. Nanobiotechnology, 15, 66, 10.1186/s12951-017-0302-5 Han, 2018, A nanomedicine approach enables co-delivery of cyclosporin a and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer, Signal Transduct. Target. Ther., 3, 16, 10.1038/s41392-018-0019-4 Chen, 2018, Biodegradable nanoparticles mediated co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) toward the treatment of ELTN-resistant non-small cell lung Cancer (NSCLC) via suppression of the JAK2/STAT3 signaling pathway, Front. Pharmacol., 9, 1214, 10.3389/fphar.2018.01214 Budillon, 2019, Identification and targeting of stem cell-activated pathways in cancer therapy, Stem Cells Int., 2019, 8549020, 10.1155/2019/8549020 Hu, 2018, CD44 promotes cell proliferation in non-small cell lung cancer, Oncol. Lett., 15, 5627 Lee-Sayer, 2018, CD44-mediated hyaluronan binding marks proliferating hematopoietic progenitor cells and promotes bone marrow engraftment, PLoS One, 13, 10.1371/journal.pone.0196011 Jeannot, 2018, Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer, J. Control. Release, 275, 117, 10.1016/j.jconrel.2018.02.024 West, 2014, New and emerging HDAC inhibitors for cancer treatment, J. Clin. Invest., 124, 30, 10.1172/JCI69738 Olsen, 2007, Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma, J. Clin. Oncol., 25, 3109, 10.1200/JCO.2006.10.2434 Piekarz, 2009, Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma, J. Clin. Oncol., 27, 5410, 10.1200/JCO.2008.21.6150 Kaga, 2017, Influence of size and shape on the biodistribution of nanoparticles prepared by polymerization-induced self-assembly, Biomacromolecules, 18, 3963, 10.1021/acs.biomac.7b00995 Harrington, 2019, Optimizing oncolytic virotherapy in cancer treatment, Nat. Rev. Drug Discov., 18, 689, 10.1038/s41573-019-0029-0 Wilson, 2011, Targeting hypoxia in cancer therapy, Nat. Rev. Cancer, 11, 393, 10.1038/nrc3064 Moyer, 2012, Targeting hypoxia brings breath of fresh air to cancer therapy, Nat. Med., 18, 636, 10.1038/nm0512-636b Horan, 2016, Treatment of non-small cell lung cancer </=2 cm in size: less may not be more, Ann. Transl. Med., 4, 503, 10.21037/atm.2016.12.59 Saraiva, 2016, Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases, J. Control. Release, 235, 34, 10.1016/j.jconrel.2016.05.044 Wei, 2020, Transferrin-binding peptide functionalized polymersomes mediate targeted doxorubicin delivery to colorectal cancer in vivo, J. Control. Release, 319, 407, 10.1016/j.jconrel.2020.01.012 Tseng, 2013, Environment acidity triggers release of recombinant adeno-associated virus serotype 2 from a tunable matrix, J. Control. Release, 170, 252, 10.1016/j.jconrel.2013.05.009 Goldberg, 2019, Improving cancer immunotherapy through nanotechnology, Nat. Rev. Cancer, 19, 587, 10.1038/s41568-019-0186-9 Sau, 2018, Multifunctional nanoparticles for cancer immunotherapy: a groundbreaking approach for reprogramming malfunctioned tumor environment, J. Control. Release, 274, 24, 10.1016/j.jconrel.2018.01.028 Mahjub, 2018, Recent advances in applying nanotechnologies for cancer immunotherapy, J. Control. Release, 288, 239, 10.1016/j.jconrel.2018.09.010 Chen, 2017, Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis, Proc. Natl. Acad. Sci. U. S. A., 114, 580, 10.1073/pnas.1614035114 Madeddu, 2018, Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: key role of interleukin-6, Haematologica, 103, e388, 10.3324/haematol.2018.191551 Gajewski, 2013, Innate and adaptive immune cells in the tumor microenvironment, Nat. Immunol., 14, 1014, 10.1038/ni.2703 Liao, 2019, Repolarization of M2 to M1 macrophages triggered by lactate oxidase released from methylcellulose hydrogel, Bioconjug. Chem., 30, 2697, 10.1021/acs.bioconjchem.9b00618